share_log

AIM ImmunoTech Announces Publication Of Phase 1 Data From Roswell Park Study On Ampligen In Early-Stage Triple-Negative Breast Cancer In The Journal For ImmunoTherapy Of Cancer

AIM ImmunoTech Announces Publication Of Phase 1 Data From Roswell Park Study On Ampligen In Early-Stage Triple-Negative Breast Cancer In The Journal For ImmunoTherapy Of Cancer

aim immunotech宣布罗斯韦尔公园研究关于早期三阴性乳腺癌中阿米芬使用的1期数据在《癌症免疫疗法杂志》上发表
Benzinga ·  11/19 08:02

AIM ImmunoTech Announces Publication Of Phase 1 Data From Roswell Park Study On Ampligen In Early-Stage Triple-Negative Breast Cancer In The Journal For ImmunoTherapy Of Cancer

aim immunotech宣布罗斯韦尔公园研究关于早期三阴性乳腺癌中阿米芬使用的1期数据在《癌症免疫疗法杂志》上发表

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发